Warm autoimmune hemolytic anemia (wAIHA) – CVAY736O12301

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Key Inclusion Criteria:

• 18 years and older at time of signing consent
• Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or relapsed after at least one line of treatment, including patients with steroid resistance, dependence or intolerance
• Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL, associated with presence of symptoms related to anemia
• The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.